The Second Journees des Cordeliers: Latest Advances in Immunotherapy Against Cancer.Business Editors/Health/Medical Writers PARIS--(BUSINESS WIRE)--Sept. 12, 2003 Immunotherapy and its applications in cancer will be the focus of the second Journees des Cordeliers in Paris from October 1-3, 2003. This international scientific event is organized by Universite Pierre et Marie Curie Curie (kürē`), family of French scientists. Pierre Curie, 1859–1906, scientist, and his wife, Marie Sklodowska Curie, 1867–1934, chemist and physicist, b. (UPMC See Ultra-Mobile PC. ) and the biopharmaceutical firm, IDM (1) See identity management. (2) (Integrated Device Manufacturer) A company that performs every step of the chip-making process, including design, manufacture, test and packaging. Examples of IDMs are Intel, AMD, Motorola, IBM, TI and Lucent. (Immuno-Designed Molecules), one of the European leaders in immunotherapy against cancer. It will be presided by Professor Herve Fridman, director of the Immunotherapy Department at Hopital Europeen Georges Pompidou (Paris) and president of the IDM Scientific Board. The Second Journees des Cordeliers will assess tumour and its micro-environment, as well as future therapeutic approaches. This congress will provide an opportunity to present and discuss the results of clinical trials on immunotherapy products derived from biotechnologies designed to fight cancer. Almost 150 researchers and clinicians from three continents will attend this congress. About twenty internationally known experts will present their work and the advances made in the treatment of cancers, including basic and applied immunology. Among them, Professor Michael Fanger (Dartmouth Medical School Dartmouth Medical School is the medical school of Dartmouth College, in Hanover, New Hampshire. The school is closely affiliated with Dartmouth-Hitchcock Medical Center (DHMC) in neighboring Lebanon, New Hampshire. ) and Professor Pierre Coulie (Universite de Louvain) will discuss therapeutic vaccines, Professor Michael Lotze (Pittsburg Cancer Institute) will discuss serum proteomic markers, and Professor Reinhard Andreesen (Regensburg University, Germany) will discuss tumor antigen tumor antigen n. Any of several antigens present in tumors induced by certain types of adenoviruses and papovaviruses or in cells transformed in vitro by those viruses. Also called neoantigen, T antigen. specific T-Cells. The Journees des Cordeliers bears the name of the UPMC Cordeliers Research Center and is the result of a successful alliance between the worlds of academics and applied research, universities and biotechnology companies. UPMC Cordeliers Research Center has set a standard for excellence in immunology research, and has an active policy of technology transfer. Its collaboration with IDM, which set up one of its research laboratories at Institut des Cordeliers, is a fine example of the collaboration between the public and private sectors. Their continuous and intense exchange of data helps optimise research parameters and accelerates the evaluation of new treatments against cancer, a disease that kills 56 million people throughout the world each year. IDM is a leading biopharmaceutical company developing a new family of immunotherapy products called Cell Drugs to fight cancer and other life-threatening diseases. IDM applies its proprietary technologies to selectively isolate, engineer, expand and activate specific cell populations which are involved in therapeutic vaccination. The Company's products are designed to boost the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. , destroy residual tumor cells, and immunize im·mu·nize v. 1. To render immune. 2. To produce immunity in, as by inoculation. im patients to prevent tumor recurrence. IDM's most advanced product is in Phase III for the treatment of ovarian cancer ovarian cancer Malignant tumour of the ovaries. Risk factors include early age of first menstruation (before age 12), late onset of menopause (after age 52), absence of pregnancy, presence of specific genetic mutations, use of fertility drugs, and personal history of breast . For more information, please visit IDM's Web site, http://www.idm-biotech.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion